Advertisement
INSM ข่าวฟอเร็กซ์
Insmed Reports Positive Topline Results From Phase 3 ARISE Study Of ARIKAYCE
Biopharmaceutical company Insmed Inc. (INSM) announced Tuesday positive topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) who had not started antibiotics.
RTTNews
|
690 วันที่ผ่านมา
